Ambu A/S (OTCMKTS:AMBBY) Rating Increased to Buy at DNB Markets
Ambu A/S (OTCMKTS:AMBBY) Rating Increased to Buy at DNB Markets
Ambu A/S (OTCMKTS:AMBBY – Get Rating) was upgraded by stock analysts at DNB Markets from a "hold" rating to a "buy" rating in a research note issued to investors on Thursday, The Fly reports.
安布 A/S (OTCMK: 安比 — 獲得評分) 《飛行》報導，DNB Markets 的股票分析師在周四發布給投資者的研究報告中，從「持有」評級提升為「買入」評級。
Separately, JPMorgan Chase & Co. increased their price target on Ambu A/S from 64.00 to 65.00 and gave the stock an "underweight" rating in a report on Wednesday, December 14th.
另外，摩根大通公司在 12 月 14 日（星期三）的報告中將其對安布 A/S 的價格目標從 64.00 提高到 65.00，並在 12 月 14 日（星期三）的一份報告中給予該股票「體重過輕」評級。
Ambu A/S Price Performance
安布A/S價格表現
OTCMKTS:AMBBY opened at $14.55 on Thursday. The company has a 50 day simple moving average of $14.35 and a two-hundred day simple moving average of $11.99. Ambu A/S has a fifty-two week low of $8.08 and a fifty-two week high of $19.25.
OTCMK：安比在周四開市 14.55 美元。該公司擁有 50 天的簡單移動平均線 14.35 美元，以及兩百天的簡單移動平均線為 11.99 美元。安布 A/S 的五十二周低點為 8.08 美元，五十二周高點為 19.25 美元。
About Ambu A/S
關於安布 A/S
(Get Rating)
(取得評分)
Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope.
Ambu A/S 從事醫院和救援服務的診斷和生命支持設備的開發，生產和銷售。它通過以下幾個部分運作：麻醉，患者監測和診斷；以及可視化。麻醉部門提供復甦、口罩和喉罩到一次性使用靈活插管範圍的產品。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Ambu A/S (AMBBY)
- Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
- Has Workhorse Group Finally Hit Bottom?
- Target Offering A Rare Buying Opportunity After Earnings
- Rivian Gives Investors a Taste of the Anxiety Its Consumers Feel
- 3 High-Yield Dividend Stocks That Are Probably Not On Your Radar
- 獲取有關安布 A/S（AMBBY）的研究報告的免費副本
- 華爾街看到 23% 上升的革新, 肉毒桿菌毒素競爭對手的製造商
- 主力集團終於打底了嗎？
- 目標提供收益後罕見的購買機會
- Rivian 為投資者提供消費者感受到的焦慮
- 3 種可能不在您的雷達上的高收益股息股票
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日安布 A/S 的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Ambu A/S 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。